WO2018088850A3 - Cd40에 특이적으로 결합하는 항체 및 그의 용도 - Google Patents

Cd40에 특이적으로 결합하는 항체 및 그의 용도 Download PDF

Info

Publication number
WO2018088850A3
WO2018088850A3 PCT/KR2017/012747 KR2017012747W WO2018088850A3 WO 2018088850 A3 WO2018088850 A3 WO 2018088850A3 KR 2017012747 W KR2017012747 W KR 2017012747W WO 2018088850 A3 WO2018088850 A3 WO 2018088850A3
Authority
WO
WIPO (PCT)
Prior art keywords
binding specifically
antibody binding
antibody
fragment
cancer
Prior art date
Application number
PCT/KR2017/012747
Other languages
English (en)
French (fr)
Other versions
WO2018088850A2 (ko
Inventor
지길용
홍권표
이의섭
문유리
윤상순
Original Assignee
다이노나(주)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다이노나(주) filed Critical 다이노나(주)
Priority to US16/348,284 priority Critical patent/US11905331B2/en
Priority to CN201780082898.3A priority patent/CN110546164B/zh
Publication of WO2018088850A2 publication Critical patent/WO2018088850A2/ko
Publication of WO2018088850A3 publication Critical patent/WO2018088850A3/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464416—Receptors for cytokines
    • A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

CD40에 특이적으로 결합하는 항 CD40 항체 및 이의 용도와 관련된 것으로, 구체적으로, 항 CD40 항체 또는 이의 항원 결합 단편, 및 이를 유효성분으로 포함하는 것으로 암, 암전이, 감염, 및 /또는 면역 결핍 질환의 예방 및 /또는 치료용 약학 조성물이 제공된다.
PCT/KR2017/012747 2016-11-11 2017-11-10 Cd40에 특이적으로 결합하는 항체 및 그의 용도 WO2018088850A2 (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US16/348,284 US11905331B2 (en) 2016-11-11 2017-11-10 Antibody binding specifically to CD40 and use thereof
CN201780082898.3A CN110546164B (zh) 2016-11-11 2017-11-10 特异性结合cd40的抗体及其用途

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160150624 2016-11-11
KR10-2016-0150624 2016-11-11

Publications (2)

Publication Number Publication Date
WO2018088850A2 WO2018088850A2 (ko) 2018-05-17
WO2018088850A3 true WO2018088850A3 (ko) 2018-07-26

Family

ID=62109888

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/012747 WO2018088850A2 (ko) 2016-11-11 2017-11-10 Cd40에 특이적으로 결합하는 항체 및 그의 용도

Country Status (4)

Country Link
US (1) US11905331B2 (ko)
KR (1) KR102019033B1 (ko)
CN (1) CN110546164B (ko)
WO (1) WO2018088850A2 (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202144421A (zh) * 2020-03-30 2021-12-01 大陸商正大天晴藥業集團股份有限公司 結合cd40的抗體及其用途
KR20240026185A (ko) * 2021-06-28 2024-02-27 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 항-cd40 항체, 항원 결합 단편 및 이의 의학적 용도
KR20230108156A (ko) * 2022-01-10 2023-07-18 주식회사 금호에이치티 Cd40l에 특이적으로 결합하는 항체 및 그의 용도

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801227A (en) * 1993-10-01 1998-09-01 Fanslow, Iii; William C. Antibodies to CD40
US20050169923A1 (en) * 1992-07-09 2005-08-04 Chiron Corporation Anti-CD40 antibodies capable of blocking B-cell activation
KR20070012626A (ko) * 2003-12-22 2007-01-26 화이자 프로덕츠 인크. Ｃｄ40 항체 제제 및 방법
KR20080030958A (ko) * 2005-05-26 2008-04-07 시애틀 지네틱스, 인크. 인간화 항-ｃｄ４０ 항체 및 그의 사용 방법
US7449616B2 (en) * 2002-12-24 2008-11-11 Pfizer Inc. Anti-NGF antibodies and methods using same
US8496937B2 (en) * 2009-03-30 2013-07-30 Edimer Pharmaceuticals, Inc. Preparation of isolated agonist anti-EDAR monoclonal antibodies
US8980257B2 (en) * 2010-05-18 2015-03-17 Medical & Biological Laboratories Co., Ltd. Antibody being capable of binding to transforming growth factor alpha and having growth-suppressing activity on cancers having Ras gene mutation
US20150309028A1 (en) * 2014-04-29 2015-10-29 Edp Biotech Corporation Methods and compositions for screening and detecting biomarkers
US20170088605A1 (en) * 2015-09-16 2017-03-30 Novartis Ag Polyomavirus neutralizing antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2243531A1 (en) * 1996-01-16 1997-07-24 The Trustees Of Columbia University In The City Of New York Therapeutic applications of t-bam (cd40-l) technology to treat inflammatory kidney diseases______________________________________
EA004401B1 (ru) * 1996-07-08 2004-04-29 Дзе Трастиз Оф Колумбия Юниверсити Ин Дзе Сити Оф Нью Йорк Терапевтическое применение т-вам(cd40l)-технологии для лечения заболеваний с участием клеток гладкой мускулатуры
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
AU2016216711B2 (en) * 2007-04-07 2018-01-25 Whitehead Institute For Biomedical Research Reprogramming of somatic cells
CN106977604A (zh) 2011-04-21 2017-07-25 百时美施贵宝公司 拮抗cd40之抗体多肽
JP6691113B2 (ja) 2014-10-29 2020-04-28 シアトル ジェネティックス， インコーポレイテッド 非フコシル化抗ｃｄ４０抗体の投与量および投与

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050169923A1 (en) * 1992-07-09 2005-08-04 Chiron Corporation Anti-CD40 antibodies capable of blocking B-cell activation
US5801227A (en) * 1993-10-01 1998-09-01 Fanslow, Iii; William C. Antibodies to CD40
US7449616B2 (en) * 2002-12-24 2008-11-11 Pfizer Inc. Anti-NGF antibodies and methods using same
KR20070012626A (ko) * 2003-12-22 2007-01-26 화이자 프로덕츠 인크. Ｃｄ40 항체 제제 및 방법
KR20080030958A (ko) * 2005-05-26 2008-04-07 시애틀 지네틱스, 인크. 인간화 항-ｃｄ４０ 항체 및 그의 사용 방법
US8496937B2 (en) * 2009-03-30 2013-07-30 Edimer Pharmaceuticals, Inc. Preparation of isolated agonist anti-EDAR monoclonal antibodies
US8980257B2 (en) * 2010-05-18 2015-03-17 Medical & Biological Laboratories Co., Ltd. Antibody being capable of binding to transforming growth factor alpha and having growth-suppressing activity on cancers having Ras gene mutation
US20150309028A1 (en) * 2014-04-29 2015-10-29 Edp Biotech Corporation Methods and compositions for screening and detecting biomarkers
US20170088605A1 (en) * 2015-09-16 2017-03-30 Novartis Ag Polyomavirus neutralizing antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE GenBank 28 April 2014 (2014-04-28), Database accession no. AHX81815.1 *

Also Published As

Publication number Publication date
CN110546164B (zh) 2023-10-20
KR20180053255A (ko) 2018-05-21
WO2018088850A2 (ko) 2018-05-17
US11905331B2 (en) 2024-02-20
KR102019033B1 (ko) 2019-09-06
US20230192875A1 (en) 2023-06-22
CN110546164A (zh) 2019-12-06

Similar Documents

Publication Publication Date Title
EP3481402A4 (en) CONNECTIONS, COMPOSITIONS AND METHODS FOR TREATING A DISEASE
EP3675859A4 (en) COMPOUNDS, COMPOSITIONS AND PROCEDURES FOR TREATMENT OF DISEASES
WO2016191643A3 (en) Tigit-binding agents and uses thereof
EP3484504A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT OF DISEASE
MX2017001976A (es) Terapia de combinacion de anticuerpos activadores de la cd40 humana y anticuerpos contra el mp-l1 humano.
MX2023002507A (es) Inhibidores de cd73.
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
EP3411504A4 (en) ANTI-TNF ANTIBODIES, COMPOSITIONS, METHODS AND USE FOR THE TREATMENT OR PREVENTION OF TYPE-1 DIABETES
EP3934652A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES
WO2015049365A3 (en) Methods and pharmaceutical compositions for modulating autophagy in a subject in need thereof
WO2017117070A8 (en) Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof
WO2016077656A3 (en) Methods and compositions for inhibition of bromodomain and extraterminal proteins
WO2017136450A3 (en) Compounds and methods of treating rna-mediated diseases
NZ788133A (en) Cd73 inhibitors
EP3685838A4 (en) COMPOSITION FOR THE TREATMENT OR PREVENTION OF OBESITY OR DISEASES RELATED TO OBESITY AND USE THEREOF
WO2016020882A3 (en) Angiopoetin-like 4 (angptl4) antibodies and methods of use
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
EP4003994A4 (en) TREATMENT OF IMMUNEVASIVE TUMORS
WO2018088850A3 (ko) Cd40에 특이적으로 결합하는 항체 및 그의 용도
MX2023004314A (es) Anticuerpos ligando anti grupo de diferenciacion 40 (cd40) terapeuticos.
IL270927B (en) fused 5,6 bicyclic compounds and compounds for the treatment of parasitic diseases
PH12017502356B1 (en) Immunoglobulin single variable domain antibody against rsv prefusion f protein
EP3162803A4 (en) New compound for inhibiting binding between dx2 protein and p14/arf protein, and pharmaceutical composition for treating or preventing cancer disease containing same as effective ingredient
EP3820477A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES
WO2019098811A3 (ko) Chp(시클로-히스프로)를 포함하는 골 손실 질환의 예방, 개선 또는 치료용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17869851

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17869851

Country of ref document: EP

Kind code of ref document: A2